Pitcairn Co. Acquires Shares of 11,745 TG Therapeutics, Inc. (NASDAQ:TGTX)

Pitcairn Co. bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 11,745 shares of the biopharmaceutical company’s stock, valued at approximately $354,000.

Other large investors have also recently made changes to their positions in the company. Arizona State Retirement System lifted its holdings in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company’s stock valued at $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. increased its position in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 371 shares during the period. Brookstone Capital Management raised its stake in shares of TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company’s stock valued at $527,000 after acquiring an additional 624 shares in the last quarter. Daymark Wealth Partners LLC boosted its holdings in shares of TG Therapeutics by 1.7% in the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company’s stock valued at $1,249,000 after purchasing an additional 689 shares during the period. Finally, New York State Teachers Retirement System grew its stake in TG Therapeutics by 1.9% in the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company’s stock worth $1,317,000 after purchasing an additional 837 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

TGTX has been the subject of a number of research analyst reports. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Down 5.1 %

Shares of NASDAQ:TGTX opened at $37.35 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $5.87 billion, a PE ratio of -373.46 and a beta of 2.13. TG Therapeutics, Inc. has a 12-month low of $12.93 and a 12-month high of $43.32. The business’s fifty day simple moving average is $35.27 and its 200-day simple moving average is $30.85.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. As a group, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.